Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) EVP John B. Moriarty sold 3,538 shares of the business’s stock in a transaction on Tuesday, February 7th. The shares were sold at an average price of $125.79, for a total transaction of $445,045.02. Following the transaction, the executive vice president now owns 46,801 shares in the company, valued at approximately $5,887,097.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 126.51 on Monday. Alexion Pharmaceuticals, Inc. has a 12 month low of $109.12 and a 12 month high of $162.00. The company has a market cap of $28.33 billion, a price-to-earnings ratio of 77.14 and a beta of 1.39. The firm’s 50-day moving average is $131.00 and its 200-day moving average is $127.05.
A number of research analysts recently issued reports on ALXN shares. FBR & Co reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Monday, November 14th. Vetr downgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $107.00 target price on the stock. in a research report on Tuesday, October 18th. Oppenheimer Holdings, Inc. started coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, December 15th. They set a “market perform” rating on the stock. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 28th. Finally, Credit Suisse Group restated an “outperform” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, December 16th. Seven investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $170.70.
Several institutional investors have recently bought and sold shares of ALXN. Bank of The West raised its position in Alexion Pharmaceuticals by 9.0% in the second quarter. Bank of The West now owns 43,444 shares of the biopharmaceutical company’s stock valued at $5,073,000 after buying an additional 3,585 shares in the last quarter. Regal Investment Advisors LLC bought a new position in Alexion Pharmaceuticals during the second quarter valued at about $2,764,000. Princeton Alpha Management LP bought a new position in Alexion Pharmaceuticals during the second quarter valued at about $3,242,000. Granite Point Capital Management L.P. bought a new position in Alexion Pharmaceuticals during the second quarter valued at about $1,168,000. Finally, Exane Asset Management bought a new position in Alexion Pharmaceuticals during the second quarter valued at about $16,516,000. 94.98% of the stock is owned by hedge funds and other institutional investors.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/insider-selling-alexion-pharmaceuticals-inc-alxn-evp-sells-445045-02-in-stock/1657621.html
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.